Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-06-09
2001-04-17
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S048000
Reexamination Certificate
active
06218399
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to derivatives of camptothecin, preferably having low toxicity, and to the use of these derivatives for cancer treatment. The disclosures of all documents referred to in this application are incorporated herein in whole by reference.
BACKGROUND OF THE INVENTION
Camptothecin, a cytotoxic alkaloid first isolated from the wood and bark of Camptotheca Acuminata (Nyssaceae) by Wall and his coworkers (
J. Am. Chem. Soc.
88, 3888, 1966), was shown to have antitumor activity against the mouse leukemia L 1210 system. The structure of camptothecin, an alkaloid which has a commonly occurring indole alkaloid group (Heckendorf et al,
J Org. Chem.
41, 2045, 1976), is shown below as Formula (X).
This compound has a pentacyclic ring system with only one asymmetrical center in ring E with a 20(S)-configuration. The pentacyclic ring system includes a pyrrolo [3, 4-b] quinoline moiety (rings A, B and C), a conjugated pyridone (ring D), and a six-membered lactone (ring E) with an &agr;—hydroxyl group. Camptothecin was of great interest from the time of its initial isolation due to its noteworthy activity in the mouse leukemia L 1210 system. Earlier data for the antitumor activity of camptothecin were obtained by employing experimentally transplanted malignancies such as leukemia L 1210 in mice, or Walker 256 tumor in rats (
Chem. Rev.
23, 385, 1973,
Cancer Treat. Rep.
60, 1007, 1967). Subsequent clinical studies showed that this compound was not usable as an anticancer agent invivo due to its high toxicity. Camptothecin itself is insoluble in water. Therefore, camptothecin was evaluated clinically as a water-soluble sodium carboxylate salt in the early times. This form of camptothecin produced severe toxicity and seemed devoid of anticancer activity (Gottlieb et al,
Cancer Chemother. Rep.
54, 461, 1970, and 56, 103, 1972, Muggia et at,
Cancer Chemother. Rep.
56, 515,1972, Moertel et al,
Cancer Chemother. Rep.
56, 95, 1972, and Schaeppi et al,
Cancer Chemother. Rep.
5:25, 1974). These results caused the discontinuation of phase II trials. Continued evaluation of this agent showed that the sodium carboxylate salt is only 10% as potent as the native camptothecin with the closed lactone ring intact (Wall et al,
In International Symposium on Biochemistry And Physiology of The Alkaloids, Mothes et al, eds, Academie —Verlag, Berlin,
77, 1969, Giovanela et al,
Cancer res.
51, 3052, 1991). In addition, important parameters for antitumor activity in the camptothecin family have been established (Wall et al,
Ann. Rev., Pharmacol Toxicol.
17, 117, 1977). These results indicate that intact lactone ring E and &agr;—hydroxyl group are essential for antitumor activity.
In 1989, Giovanella et al. found that some of the non-water soluble derivatives of camptothecin have high antitumor activity against xenograft of human tumors (Giovanella et al.,
Science,
246, 1046, 1989). It has also been shown that administration of camptothecin with closed lactone ring is superior to injections of water-soluble carboxylate salt (Giovanella et al,
Cancer Res.,
51, 3052, 1991). These findings further confirmed the importance of the intact lactone ring.
Clearly, there is a need to modify 20(S)-camptothecin (“CPT”) to enable the lactone form to stay longer in the body while retaining the structural elements (i.e. 20-hydroxyl and lactone ring E) which are essential for its antitumor activity.
Ring opening of CPT leads to much more potent anticancer activity in mice than in humans. In effect, CPT administered intramuscularly (“i.m.”), subcutaneously (“s.c.”), and intrastomach (“i.s.”) has proved to be a very potent anticancer agent against human tumors in mice, i.e., when growing as xenotransplants in nude mice (Giovanella et al, Cancer Res. 51:3052, 1991). However, when tumors were treated with CPT in humans, a lower degree of anticancer activity in humans, than in mice, was exhibited (Stehlin et al., In Camptothecins: New Anticancer Agents, 1995, CRC Press, pp. 59-65).
The same phenomenon was observed with other CPT derivatives. In mice, 9-nitrocamptothecin (“9NC”) has proven to be 2-3 times more potent than CPT against human tumor xenografts causing the total eradication of all the human malignancies treated (Pantazis et al., Cancer Res. 53:1577, 1993; Pantazis et al., Int. J. Cancer 53:863, 1995).
Pharmacological studies demonstrated that the majority (57%) of the 9NC drug present in the plasma after i.s. administration is in the closed lactone form (FIG.
3
). Pharmacological studies on the plasma levels of 9NC after oral administration to Phase I clinical trail patients demonstrate that, on average, only ~3% of the drug present is in the closed lactone form (FIGS.
4
and
5
).
In perfect agreement with such findings, the clinical responses in this group of patients, although higher than those obtained with CPT are still a far cry below the results obtained in mice (32/32 complete tumor regressions in mice versus 2/32 in humans). Clearly, again there is a pressing need for a modification which will slow and delay the lactone ring opening upon its entrance into the blood circulation.
A number of attempts have made to provide more active derivatives of camptothecin, but none of these compounds has been disclosed to be able to delay the opening of the lactone ring E.
SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide new CPT derivatives which are effective antitumor agents, preferably useful for the oral and intramuscular routes of drug administration.
It is another object of the present invention to provide new active CPT derivatives which sustain the opening of the lactone ring E, which makes the antitumor activity last longer than its mother analog, CPT.
It is still another object of the present invention to provide new CPT derivatives which retain significant antitumor activity as does the mother compound, CPT, and have much lower toxicity than its mother compound.
It is still another object of the present invention to provide new CPT derivatives possessing good absorbability in the living body.
It is a further object of the present invention to provide new CPI derivatives which retain the lactone ring E and the 20- hydroxyl group intact, which are important for antitumor activity.
It is still a further object of the present invention to provide a method for preparing CPT derivatives.
Additional objects and advantages of the present invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. The objects and advantages of the present invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
To achieve the objects and in accordance with the purpose of the present invention, as embodied and broadly described herein, the present invention relates to a compound of formula (I):
wherein R
2
is H or NO
2
, and R
1
is a C
2
-C
4
alkyl group, a C
6
-C
15
alkyl group, a C
3
-C
8
cycloalkyl group, a C
2
-C
15
alkenyl group, or an epoxy group when R
2
is H; and R
1
is a C
1
-C
15
alkyl group, a C
1
-C
15
alkenyl group, a C
3
-C
8
cycloalkyl group, or an epoxy group when R
2
is NO
2
.
The invention also relates to a method for treating malignant tumors in a mammal and comprises administering an effective amount of one or more of the above compounds.
REFERENCES:
patent: Re. 32518 (1987-10-01), Miyasaka et al.
patent: 3894029 (1975-07-01), Winterfeldt et al.
patent: 4399282 (1983-08-01), Miyasaka et al.
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4894456 (1990-01-01), Wall et al.
patent: 4914205 (1990-04-01), Sawada et al.
patent: 4943579 (1990-07-01), Vishnuvajjala
patent: 5053512 (1991-10-01), Wani et al.
patent: 5106742 (1992-04-01), Wall et al.
patent: 5122383 (1992-06-01), Heiber et al.
patent: 5126351 (1992-06-01), Luzzio et al.
patent: 5180722 (1993-01-01), Wall et al.
patent: 5225404 (1993-07-0
Cao Zhisong
Giovanella Beppino C.
Ghali Isis
Kilyk & Bowersox P.L.L.C.
Page Thurman K.
The Stehlin Foundation for Cancer Research
LandOfFree
Derivatives of camptothecin and methods of treating cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of camptothecin and methods of treating cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of camptothecin and methods of treating cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2459050